TICKERNERD
Menu
VIRVIRHealthcare · Biotechnology

VIR Stock Forecast: Vir Biotechnology, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$11
−3.47% on the day

The 10 Wall Street analysts covering Vir Biotechnology, Inc. hold a median 12-month price target of $20 — +79.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 93 of 100 as at 8 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.9B
Ticker Nerd rank
93 / 100
Median analyst target
$20
Analysts covering
10
Revenue$238.9M+23075.1% y/y
Operating income$73.5M
Net income$80.1M
Free cash flow$123.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.5%
1M
−0.5%
YTD
+84.4%
1Y
+83.8%
From 52W high
−5.6%
From 52W low
+117.2%
$5
$12
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VIR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Vir Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
93 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
99
Value
91
Momentum
90
Quality
86
Revisions
64
Volatility
63
Issuance
50
Accruals
47
Size
36

Growth (99): Sales and profits are climbing, and climbing faster than before.

Accruals (47): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (36): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VIR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VIR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26VIRHigh $30Median $20Low $15

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $15Median $20High $30

The green dot is the last close — the median target sits +79.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Oct 2026HC Wainwright & Co.MaintainsBuy$20 → $22
11 June 2026Morgan StanleyMaintainsOverweight$23 → $27
3 June 2026Leerink PartnersMaintainsOutperform—
4 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Feb 2026BarclaysMaintainsOverweight—
24 Feb 2026Evercore ISI GroupMaintainsOutperform—
24 Feb 2026Morgan StanleyMaintainsOverweight—
24 Feb 2026NeedhamMaintainsBuy—
9 Feb 2026NeedhamReiteratesBuy—
30 Dec 2025HC Wainwright & Co.ReiteratesBuy—
15 Sept 2025HC Wainwright & Co.ReiteratesBuy—
3 Sept 2025Evercore ISI GroupInitiatesOutperform—
27 Aug 2025B of A SecuritiesUpgradeBuy—
11 July 2025Raymond JamesInitiatesOutperform—
22 May 2025NeedhamReiteratesBuy—
12 May 2025NeedhamMaintainsBuy—
17 Apr 2025Goldman SachsMaintainsBuy—
28 Feb 2025BarclaysMaintainsOverweight—
28 Feb 2025HC Wainwright & Co.ReiteratesBuy—
27 Feb 2025NeedhamReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VIR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VIR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Vir Biotechnology, Inc. returned +83.8% against +16.2% for the S&P 500, dividends included.

VIR vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200Jan 26Apr 26Jul 26Oct 26VIRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VIR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
4
Fundamentals

Vir Biotechnology, Inc. (VIR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.5×

Cheaper than 88% of US stocks

Price / sales
6.1×

Cheaper than 20% of US stocks

Price / book
1.9×

Cheaper than 46% of US stocks

EV / EBITDA
−5.7×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
19582.5%

Higher than 99% of US stocks

Earnings growth (YoY)
23075.1%

Higher than 99% of US stocks

Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
30.7%

Higher than 88% of US stocks

Net margin
−83.0%

Higher than 7% of US stocks

Returns & dividend
Return on equity
−26.1%

Higher than 29% of US stocks

Return on assets
−14.5%

Higher than 23% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Vir Biotechnology, Inc. (VIR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Vir Biotechnology, Inc. has a market value of $1.9B and an enterprise value of $1.5B.

  • Revenue in the twelve months to 30 June 2026: $302.6M. The latest quarter grew 19582.5% year on year.

  • Net income over the same four quarters: −$251.7M, a −83.2% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.86.

  • Free cash flow in the twelve months to 30 June 2026: −$203.6M.

  • Shares outstanding: 169.2M.

  • Trailing P/E: −3.5×; forward P/E: −4.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Vir Biotechnology, Inc. employs 367 people — $824K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

VIR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VIRVir Biotechnology, Inc.$1.9B
93
PVLAPalvella Therapeutics, Inc.$1.9B
31
ADRXADARx Pharmaceuticals, Inc.$1.9B
0
AGIOAgios Pharmaceuticals, Inc.$1.9B
81
MRVIMaravai Lifesciences Holdings, Inc.$1.8B
88
SRPTSarepta Therapeutics, Inc.$1.9B
71
FTREFortrea Holdings, Inc.$1.9B
97

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Vir Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VIR news & analysis

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

Business Wire · 8 Oct 2026positive

Vir Biotechnology announced that the FDA granted Fast Track designation to VIR-5500, a PSMA-targeted dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer. The candidate is being co-developed with Astellas Pharma through a global strategic collaboration.

Why it matters — The designation is a regulatory development for a Vir co-developed oncology candidate and its prostate cancer program.

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Business Wire · 7 Oct 2026positive

Vir Biotechnology appointed David Liu, M.D., Ph.D., as executive vice president and chief medical officer, effective October 12, 2026. He will lead clinical development, medical affairs and regulatory affairs.

Why it matters — The appointment sets leadership for VIR’s clinical development, medical affairs and regulatory affairs functions.

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD's The Liver Meeting® 2026

Business Wire · 5 Oct 2026positive

Vir Biotechnology announced it will present expanded Phase 2 SOLSTICE trial data on the combination of elebsiran and tobevibart for chronic hepatitis delta at AASLD's The Liver Meeting 2026 in Denver, November 5-9, 2026. The presentation will cover efficacy patterns of HDV RNA in trial participants.

Why it matters — The expanded data presentation highlights progress in Vir's hepatitis delta pipeline and provides an upcoming opportunity for investors to gauge the clinical performance of its elebsiran and tobevibart combination.

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

Business Wire · 1 Oct 2026neutral

Vir Biotechnology announced the appointment of Aziz Sawaf as Chief Financial Officer. The announcement was made by the company via Business Wire.

Why it matters — A change in the Chief Financial Officer role is relevant to VIR watchers as it affects the company's financial leadership and reporting.

Vir Biotechnology: Astellas Deal Highlights The Platform's Value

Seeking Alpha · 29 Sept 2026positive

Vir Biotechnology is described as a two-engine company, with major pharma partnerships and a fully enrolled hepatitis delta phase 3 program. The Astellas deal validates VIR's PRO-XTEN platform, providing $335 million in upfront and near-term payments plus a premium equity investment, while Gilead's bulevirtide launch is expanding hepatitis delta diagnosis, indirectly benefiting VIR's upcoming ECLIPSE trials targeting bulevirtide non-responders.

Why it matters — A VIR watcher would care because the Astellas partnership and expanding hepatitis delta market could strengthen the company's platform value and pipeline prospects.

FAQ

Frequently asked questions about VIR stock

What is the VIR stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Vir Biotechnology, Inc. have a median 12-month price target of $20, with estimates ranging from $15 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VIR stock a buy right now?

Of the 10 analysts covering Vir Biotechnology, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Vir Biotechnology, Inc. 93 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VIR?

As at 8 Oct 2026, Vir Biotechnology, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).

Will VIR stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +79.9% from the last close, and Ticker Nerd's factor model ranks Vir Biotechnology, Inc. 93 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VIR stock forecast for 2030?

No analyst covering Vir Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VIR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $15 to $30 over the next 12 months.

How has VIR stock performed over the past year?

Vir Biotechnology, Inc. returned +83.8% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Vir Biotechnology, Inc. do?

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer.

What is the latest news on VIR?

The most recent item we track (Business Wire, 8 Oct 2026): "Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer". Vir Biotechnology announced that the FDA granted Fast Track designation to VIR-5500, a PSMA-targeted dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer. The candidate is being co-developed with Astellas Pharma through a global strategic collaboration.

Company

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for serious infectious diseases and cancer. The company centers its work on immune-based approaches, including antibody therapeutics and T cell-engaging technologies, to address conditions with significant unmet medical need. Its current portfolio includes programs for chronic hepatitis delta and chronic hepatitis B, alongside multiple solid-tumor candidates built on its PRO-XTEN masking platform. Vir Biotechnology also maintains preclinical research across infectious diseases and oncology, reflecting a pipeline that spans both treatment and prevention. Headquartered in San Francisco, California, Vir Biotechnology plays a role in the broader biotechnology market as a research-driven developer of advanced therapeutic candidates.

CEO Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. · 367 employees · United States · https://www.vir.bio